The Burkinabé government has taken a significant step towards enhancing its pharmaceutical sector with the establishment of FASO-PHARMA, a company tasked with managing the integrated pharmaceutical technopole in Kokologho. This development was made possible through authentic acts dated June 22, 2026, drafted by Notary Maître Lucie TIENDREBEOGO. FASO-PHARMA is a mixed-economy company with its headquarters located in Kokologho.
FASO-PHARMA's establishment aims to create an ideal environment for industrial production of health products, develop scientific research programs, and provide logistical and energy facilities for investors. The company's capital is set at 5 billion Francs CFA, divided into 500,000 shares of 10,000 Francs CFA each. The capital has been fully paid up to 3.25 billion Francs CFA. This structure is expected to drive growth and innovation in Burkina Faso's pharmaceutical industry.
The company's objectives include offering a conducive environment for investors, conducting actions to attract and facilitate investments, and managing the technopole's land and resources sustainably. FASO-PHARMA will also focus on ensuring a secure and hospitable climate for businesses and providing necessary support to technopole investors. Additionally, the company will seek financing for projects and activities, develop partnerships, and enhance the competitiveness of health products.
Key appointments have been made to lead FASO-PHARMA, with Liliane Marie Aline GOUNABOU named Director General and Boumbéwendin Gérard Josias YAMEOGO appointed President of the Board of Administration. The company's notary, Maître Lucie TIENDREBEOGO, has been instrumental in the company's formation. The constitutive acts of FASO-PHARMA were deposited at the Ouagadougou Tribunal de Grande Instance on July 14, 2026.
The company's registration and credit mobilization details were finalized on July 14, 2026, under the number BF-KDG-01-2026-B15-00353. The technopole in Kokologho is expected to become a hub for pharmaceutical production and innovation, contributing significantly to Burkina Faso's economic growth. FASO-PHARMA's creation aligns with the government's efforts to boost the country's health sector.
The Burkinabé government's initiative to establish FASO-PHARMA demonstrates its commitment to developing the country's pharmaceutical industry. The company's focus on research, innovation, and investment attraction is expected to have a positive impact on the sector. With its registered office in Ouagadougou, FASO-PHARMA is poised to play a crucial role in enhancing access to quality health products.
As FASO-PHARMA begins operations, it will work closely with stakeholders to achieve its objectives. The company's establishment marks a significant milestone in Burkina Faso's efforts to strengthen its health sector. With a clear vision and strategy in place, FASO-PHARMA is well-positioned to drive growth and innovation in the pharmaceutical industry.
Key points
- FASO-PHARMA's establishment aims to create an ideal environment for industrial production of health products in Burkina Faso.
